NEWSROOM

Orlando

Immune Therapeutics Inc. Provides Updates and Guidance on Reverse Stock Split and Name Change

Aug 7, 2020

Awaiting completion of FINRA approval process ORLANDO, Fla., February 11, 2020 -- Immune Therapeutics, Inc. (OTC PINK: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases today announced an update on the pending 1000 to 1 reverse stock split and name change of Immune Therapeutics. Immune Therapeutics originally submitted the reverse and name request for...

read more

Immune Therapeutics Announces Plan to Acquire Aletheia Therapeutics to Create a New Precision Oncology Company

Aug 7, 2020

The Planned Acquisition Would Enhance the Management Team, Provide Capital and Bring Additional Oncology Assets to Immune’s Pipeline   ORLANDO, Fla., December 16th, 2019  -- -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company") and Aletheia Therapeutics Corp. (“Aletheia”), a privately held development-stage oncology therapeutics company, today announced that Immune will acquire Aletheia in an all-stock transaction.  Pursuant to completion of a definitive agreement,...

read more

Elev8 Brands, Inc. Eliminates Over 2.7 Million Preferred Shares

Aug 7, 2020

  ORLANDO, FL -- December 4, 2019  -- -- Elev8 Brands, Inc. (OTCQB: VATE), a holding company focused on the commercial development of hemp and cannabinoid-infused beverages along with an array of CBD topicals and tinctures, announces an exchange agreement to eliminate all 2,746,732  of Kona Gold Solutions’ Preferred Series D shares. In a contract between the two companies, Kona Gold Solution has agreed to exchange its Preferred Series D shares into a $1,500,000 non-convertible promissory note...

read more

Immune Therapeutics Today Announces Approval of a Reverse Stock Split and Name Change

Aug 7, 2020

    ORLANDO, Fla., October 28, 2019 — – Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage oncology biopharmaceutical company focused on the development therapies for the treatment of cancer using an immune therapy  and a systems biology approach today announced that its Board of Directors and a majority of its shareholders have approved a reverse stock split of the Company’s issued and outstanding common shares at a ratio of 1,000 to 1 and a...

read more

Immune Therapeutics, Inc. Announces Advisory Board Appointments

Aug 7, 2020

  ORLANDO, Fla., October 22, 2019 -- -- Immune Therapeutics, Inc. (OTCQB: IMUN) ("Immune" “IMUN” or the "Company"), a clinical late-stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that Dr. Robert Buckheit, Jr. will join the Scientific Advisory Board (“SAB”) of Immune Therapeutics. ”Immune Therapeutics is fortunate to have an individual as capable as Dr. Buckheit helping...

read more

Elev8 Brands Announces New Flavors, Packaging and Distribution Partner

Aug 7, 2020

Central Florida holding company continues to grow in the CBD-infused beverage market   ORLANDO, FL -- October 23, 2019 - -Elev8 Brands, Inc. (OTCQB: VATE), a holding company focused on the commercial development of hemp and cannabinoid-infused beverages along with an array of CBD topicals and tinctures, announces growth of subsidiary Elev8 Hemp, LLC, through product expansion and repackaging of ready-to-drink CBD-infused iced tea, as well as a new distribution partner.   “CBD has incredible...

read more

Immune Therapeutics Inc. Management Advises All Shareholders to Vote Their Proxy Card Today

Aug 7, 2020

                Immune Therapeutics Inc. Management Urges Shareholders to Vote Yes and Support the Company's Three Proposals   ORLANDO, FL – September 26, 2019 – – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today urges shareholder to vote yes for all three proposals. Immune...

read more

Immune Therapeutics Inc Advises All Shareholders to Vote Their Proxy Card Today

Aug 7, 2020

      Immune Therapeutics Inc Urges Shareholders to Vote Yes and Support the Company's Three Proposals   ORLANDO, FL – September 17, 2019) -- – Immune Therapeutics, Inc. (OTC: IMUN) ("Immune," “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today urges shareholder to vote yes for all three proposals. Over the last week...

read more

Immune Therapeutics Today Announces Appointment of Michael K. Handley as its new Chief Executive Officer and Member of the Board of Directors

Aug 7, 2020

          ORLANDO, Fla., September 23, 2019 — –Immune Therapeutics, Inc. (OTC: IMUN) (IMUN) (“Immune” “IMUN” or the “Company”), a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammatory conditions, cancer, HIV/AIDS and animal diseases on a global basis is pleased to announce the appointment of Michael K. Handley as the new Chief Executive Officer of Immune Therapeutics’ and Member of the Board...

read more

Elev8 Brands Inc. Introduces New CBD Whole Bean Coffee And Single Serve Hemp Coffee

Aug 7, 2020

Projected Fourth Quarter Revenues Over $400,000 ORLANDO, FL -- September 17, 2019  -- -- Elev8 Brands, Inc. (OTCQB: VATE), a holding company focused on the commercial development of hemp and cannabinoid-infused beverages along with an array of CBD topicals and tinctures, announces a new hemp infused single serve coffee as well as advancement into CBD whole bean coffee. Elev8 Hemp, LLC is eager to expand its coffee presence into the single serve market. The Company has received many requests...

read more

Elev8 Hemp Reorders 100,000 CBD Tea Bottles

Aug 7, 2020

Company defines identity with new logo and label design   ORLANDO, FL -- September 6, 2019 -- -- Elev8 Brands, Inc. (OTCQB: VATE), a holding company focused on the commercial development of hemp and cannabinoid-infused beverages along with an array of CBD topicals and tinctures, announces a reorder of 100,000 units of its ready to drink CBD infused iced tea along with a bold new look as it continues to gain national attention. Elev8 Hemp’s new order will feature a creative new design around...

read more

IGEX WELCOMES MARTINA LEON AS NEW CEO

Aug 7, 2020

Orlando, FL -- August 20, 2019  -- -- On May 6th 2019, HuLogix, Inc a Florida company, became a wholly owned subsidiary of Indo Global Exchange(s) PTE LTD (OTC: IGEX) On August 16th Martina Leon was appointed CEO of IGEX. Now is the right time for a leadership change and Martina is the right person to guide IGEX/HuLogix through the coming era. Martina has 27 years in the medical management field with 15 years in clinical trials.  Martina has taken previous business from $450k revenue to over...

read more

Elev8 Brands, Inc. Reports Astonishing Q2 Growth

Aug 7, 2020

Distribution Network Expands & Company Reports First Profitable Month ORLANDO, FL -- August 16, 2019  --  -- Elev8 Brands, Inc. (OTCQB: VATE), a holding company focused on the commercial development of hemp and cannabinoid-infused beverages along with an array of CBD topicals and tinctures, announces impressive second quarter financials and new distribution contracts. Coming off an extremely promising first quarter, Elev8 Brands, Inc. has continued their upward trajectory for the year,...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »